$266 Million is the total value of Aquilo Capital Management, LLC's 13 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $44,758,568 | +11.1% | 1,103,515 | -9.4% | 16.81% | +15.8% |
| XBI | S&P BIOTECH ETF TRput | $41,500,000 | +4.6% | 500,000 | 0.0% | 15.59% | +9.0% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $25,487,256 | -26.2% | 581,768 | +11.0% | 9.57% | -23.1% |
| ARVN | Buy | ARVINAS INC | $23,055,522 | -22.9% | 673,941 | +0.3% | 8.66% | -19.6% |
| MRUS | Sell | MERUS N V | $22,154,726 | -26.6% | 1,432,109 | -5.0% | 8.32% | -23.5% |
| RGNX | Sell | REGENXBIO INC | $20,359,473 | -20.4% | 897,684 | -7.2% | 7.65% | -17.0% |
| SLN | Buy | SILENCE THERAPEUTICS PLCads | $19,583,028 | +54.5% | 1,284,133 | +1.7% | 7.36% | +61.0% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $15,710,099 | +118.5% | 629,411 | +90.6% | 5.90% | +127.7% |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $15,322,649 | +10.8% | 2,098,993 | +5.0% | 5.76% | +15.4% |
| QURE | Sell | UNIQURE NV | $14,165,440 | -10.3% | 624,854 | -25.7% | 5.32% | -6.5% |
| GMAB | Sell | GENMAB A/Ssponsored ads | $10,291,898 | +30.8% | 242,848 | -0.8% | 3.87% | +36.3% |
| ARGX | ARGENX SEsponsored adr | $9,091,920 | +7.3% | 24,000 | 0.0% | 3.42% | +11.8% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $4,734,991 | +2.0% | 4,552,876 | +12.8% | 1.78% | +6.3% |
| FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -3,573 | -100.0% | -0.01% | – |
| SPRO | Exit | SPERO THERAPEUTICS INC | $0 | – | -3,403,210 | -100.0% | -2.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.